Impact of biomarkers on clinical trial risk in breast cancer

Jayson L. Parker, Nadia Lushina, Prabjot S. Bal, Teresa Petrella, Rebecca Dent, Gilberto Lopes

Research output: Contribution to journalArticle

Abstract

We determined the success rate of new drug approval by the US FDA in two breast cancer indications, one of which used a biomarker. This allowed us to assess if biomarkers improved clinical trial risk in breast cancer. We performed a retrospective screening of industry-sponsored drug development programs registered on clinicaltrials.gov from 1998 to 2012 for HER2-positive patients compared to patients that had either failed or had been exposed to anthracycline or taxane, whose first phase I in this indication occurred no earlier than 1998. Compounds not registered on clinicaltrials.gov and studied exclusively outside the US were excluded. Twenty-nine drugs for HER2-positive patients and 28 drugs for anthracycline/taxane-exposed patients met our screening criteria. The overall success rate of new drug development in anthracycline/taxane patients was only 15 %, while in HER2-positive patients it was 23 %. However, HER2-targeted therapies underperformed compared to broad acting agents. The cost for clinical trial testing alone, when adjusted for the risk of failure, for HER2-positive breast cancer patients was $199 million, significantly lower than the cost of $274 million for anthracycline/taxane-experienced patients. The use of a validated biomarker, such as HER2, reduced clinical trial risk by as much as 50 % resulting in cost savings of 27 % in advanced and metastatic breast cancer. However, these data have to be evaluated in a context in which studies combining a novel drug with a novel biomarker not yet recognized by the FDA may actually increase clinical trial risk.

Original languageEnglish (US)
Pages (from-to)179-185
Number of pages7
JournalBreast Cancer Research and Treatment
Volume136
Issue number1
DOIs
StatePublished - Nov 1 2012

Keywords

  • Biomarker
  • Clinical trial
  • HER2
  • Metastatic breast cancer
  • Pharmacogenomics
  • Risk

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Impact of biomarkers on clinical trial risk in breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Parker, J. L., Lushina, N., Bal, P. S., Petrella, T., Dent, R., & Lopes, G. (2012). Impact of biomarkers on clinical trial risk in breast cancer. Breast Cancer Research and Treatment, 136(1), 179-185. https://doi.org/10.1007/s10549-012-2247-6